Control Bionics (ASX: CBL) registers NeuroStrip with US FDA as commercial execution becomes the next test
Read More Pharma Industry News Why hereditary angioedema could become Intellia Therapeutics’ biggest CRISPR validation test Find out how Intellia’s lonvo-z Phase 3 data could reshape HAE treatment and investor sentiment around in vivo CRISPR. bySoujanya RaviJune 15, 2026